Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

BUY
$10.48 - $16.94 $453,731 - $733,417
43,295 New
43,295 $659,000
Q1 2020

May 13, 2020

SELL
$16.4 - $41.77 $126,197 - $321,420
-7,695 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$19.75 - $33.44 $151,976 - $257,320
7,695 New
7,695 $202,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $390M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Landscape Capital Management, L.L.C. Portfolio

Follow Landscape Capital Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.